01
Cash & equivalents decreased 3.6%
Cash & equivalents changed -3.6% from the comparable as-filed period.
$13.8M→$13.3MComparable → current
· Pharmaceutical Preparations
RESEARCH SNAPSHOTGALECTIN THERAPEUTICS INC's latest supported as-filed period reports net income of -$9.1M, 21.2% below the comparable as-filed period. Every value below links to its SEC accession and metric lineage.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
Cash & equivalents changed -3.6% from the comparable as-filed period.
Net income changed -21.2% from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes.
Operating income changed +13.9% from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes.
Each point keeps the date investors could first observe it and its accession.
GALT · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001140361-26-032946SEC ↗10-QAug 14, 2026Period Jun 30, 20260001140361-26-032945SEC ↗4Aug 4, 2026Period Jul 31, 20260001133416-26-000065SEC ↗8-KAug 4, 2026Period Jul 31, 20260001140361-26-031058SEC ↗4Jul 16, 2026Period Jul 14, 20260001133416-26-000063SEC ↗4Jun 30, 2026Period Jun 26, 20260001133416-26-000061SEC ↗4Jun 30, 2026Period Jun 26, 20260001133416-26-000059SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Jul 31, 2026Filed Aug 4, 2026 | Uihlein Richard EDirector | Option ExerciseIndirect | 31,825,235 | $3 | $95.5M | Form 4 ↗ |
| Jul 31, 2026Filed Aug 4, 2026 | Uihlein Richard EDirector | Option ExerciseIndirect | 2,550,932 | $4 | $10.3M | Form 4 ↗ |
| Jul 31, 2026Filed Aug 4, 2026 | Uihlein Richard EDirector | Option ExerciseIndirect | — | $95.5M | — | Form 4 ↗ |
| Jul 31, 2026Filed Aug 4, 2026 | Uihlein Richard EDirector | Option ExerciseIndirect | — | $10.3M | — | Form 4 ↗ |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Research & development changed -34.5% from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes.
Stock-based compensation changed +92.6% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001133416-26-000057